Figure 1 | British Journal of Cancer

Figure 1

From: Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinum

Figure 1

Greatest percentage change from baseline in sum of longest diameters (A). Progression-free survival and OS times (B). *Progressive disease because of appearance of new metastatic lesions or unequivocal progression of non-target lesions. †Unconfirmed PR. Abbreviations: PD=progressive disease; SD=stable disease.

Back to article page